11/18/2011

The FDA gave priority-review status for Northera, Chelsea Therapeutics' drug candidate for neurogenic orthostatic hypotension, a condition associated with Parkinson's disease. The agency, which designated Northera an orphan medicine, is expected to decide on approval by March 28.

Full Story:
MedCityNews.com

Related Summaries